Trial Profile
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Breast Cancer Whose Disease Has Failed Prior Taxane-Based Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2019
Price :
$35
*
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nektar Therapeutics
- 19 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 03 Oct 2013 Results published in the Lancet Oncology.
- 25 Apr 2012 Actual end date (1 Jan 2012) added as reported by ClinicalTrials.gov.